Dean Maglaris is CEO and Chairman of the Board of Managers for Cytogel Pharma. Mr. Maglaris is a seasoned leader with more than 30 years in the pharmaceutical industry, joining Cytogel as its CEO in 2005. He has successfully guided the company through the identification of attractive compounds and the development of its lead compound, CYT-1010, which is entering Phase 2 clinical development, following a successful Phase 1 study in humans. Mr. Maglaris has long understood the need for a breakthrough solution to effectively and safely treat moderate to severe pain and has recognized the potential benefits CYT-1010 could provide to patients. As such, Cytogel has a clear priority on developing this new class of drugs and continually pursuing new intellectual property, which has resulted in several issued patents.
Understanding the benefits that critical drug development can have on patients, Mr. Maglaris held leadership positions at Pfizer ranging from general management, product and business development and marketing. His experience covers the spectrum of major therapeutic areas in pharmaceuticals as well as a wide array of medical device markets in the U.S. and worldwide. As Group Vice President and General Manager, he was instrumental in the development and launch of several products that became major successes, with several achieving annual sales in excess of $2.0 billion each. He attributes that success to focusing on discovering and developing drug solutions that actually address the needs of the patients and their providers, in a meaningful and comparatively better way.
Mr. Maglaris is active in the industry and has participated as a member of the Pharmaceutical Research and Manufacturers of America and the Biotechnology Industry Organization. He served as the Chair of the Board of Trustees of the University of Vermont, Chairman of the Board of Directors of the AmeriCares Foundation and an officer of the Board of Trustees of the New Canaan Country School in New Canaan, CT. He holds a B.S. degree from the University of Vermont and an MBA from Northeastern University.
Dean Maglaris is CEO and Chairman of the Board of Managers for Cytogel Pharma. Mr. Maglaris is a seasoned leader with more than 30 years in the pharmaceutical industry, joining Cytogel as its CEO in 2005. He has successfully guided the company through the identification of attractive compounds and the development of its lead compound, CYT-1010, which is entering Phase 2 clinical development, following a successful Phase 1 study in humans. Mr. Maglaris has long understood the need for a breakthrough solution to effectively and safely treat moderate to severe pain and has recognized the potential benefits CYT-1010 could provide to patients. As such, Cytogel has a clear priority on developing this new class of drugs and continually pursuing new intellectual property, which has resulted in several issued patents.
Understanding the benefits that critical drug development can have on patients, Mr. Maglaris held leadership positions at Pfizer ranging from general management, product and business development and marketing. His experience covers the spectrum of major therapeutic areas in pharmaceuticals as well as a wide array of medical device markets in the U.S. and worldwide. As Group Vice President and General Manager, he was instrumental in the development and launch of several products that became major successes, with several achieving annual sales in excess of $2.0 billion each. He attributes that success to focusing on discovering and developing drug solutions that actually address the needs of the patients and their providers, in a meaningful and comparatively better way.
Mr. Maglaris is active in the industry and has participated as a member of the Pharmaceutical Research and Manufacturers of America and the Biotechnology Industry Organization. He served as the Chair of the Board of Trustees of the University of Vermont, Chairman of the Board of Directors of the AmeriCares Foundation and an officer of the Board of Trustees of the New Canaan Country School in New Canaan, CT. He holds a B.S. degree from the University of Vermont and an MBA from Northeastern University.
Dr. Maione has extensive experience in research, management and product development in the biotechnology industry. He has served as an officer at three companies that developed novel pharmaceutical products. At Cytogel, Dr. Maione coordinates all research and development efforts and has been instrumental in identifying Cytogel’s primary products and creating its licensing and development strategy. He has piloted Cytogel’s CYT-1010 program and presented preclinical and clinical results at national meetings and international congresses.
Prior to joining Cytogel, Dr. Maione was the Chief Scientific Officer and Vice President of Research and Development at Seroptix. Prior to that time, he directed preclinical research for an amino acid prodrug that entered Phase III clinical trials for treatment of ARDS and SIRS while at Transcend Therapeutics.
Dr. Maione also served as President and Chief Scientific Officer for Repligen Development Corp, an LLP formed to specifically advance the clinical development of Platelet Factor 4, an effective heparin reversal agent that successfully demonstrated activity in Phase 2 testing. Previously at Repligen Corp., he held research, management and product development positions with responsibility for advancing novel therapeutic proteins and peptides from the lab into clinical development. Dr. Maione received a BS from Michigan State, a PhD from Cornell and conducted post doctoral research at Brandeis.
Dr. Maione has extensive experience in research, management and product development in the biotechnology industry. He has served as an officer at three companies that developed novel pharmaceutical products. At Cytogel, Dr. Maione coordinates all research and development efforts and has been instrumental in identifying Cytogel’s primary products and creating its licensing and development strategy. He has piloted Cytogel’s CYT-1010 program and presented preclinical and clinical results at national meetings and international congresses.
Prior to joining Cytogel, Dr. Maione was the Chief Scientific Officer and Vice President of Research and Development at Seroptix. Prior to that time, he directed preclinical research for an amino acid prodrug that entered Phase III clinical trials for treatment of ARDS and SIRS while at Transcend Therapeutics.
Dr. Maione also served as President and Chief Scientific Officer for Repligen Development Corp, an LLP formed to specifically advance the clinical development of Platelet Factor 4, an effective heparin reversal agent that successfully demonstrated activity in Phase 2 testing. Previously at Repligen Corp., he held research, management and product development positions with responsibility for advancing novel therapeutic proteins and peptides from the lab into clinical development. Dr. Maione received a BS from Michigan State, a PhD from Cornell and conducted post doctoral research at Brandeis.
Dr. Hamsher is responsible for Licensing and Business Development activities at Cytogel and has extensive experience in the pharmaceutical industry in licensing as well as research and development. Responsibilities at Cytogel have included initiating and maintaining relationships with industry experts and pharmaceutical companies around the world, which includes dissemination of key information, making presentations and involvement in business decisions relating to licensing activities. In addition to Business Development, Dr. Hamsher is involved in the research, development, and planning of Cytogel’s new drug candidate, CYT-1010.
Prior to joining Cytogel in 2008, Dr. Hamsher was President of Hamsher Associates International, a private Healthcare consulting company. Much of his professional career was with Pfizer, Inc., most recently as Senior Director of Licensing and Business Development for worldwide pharmaceuticals. Responsibilities included new drug discovery, evaluation, deal structure and negotiation, and presentation of overall projects to Senior Management for approval. Most notable during this tenure was responsibility for the early stage licensing and deal structure/negotiation for the multi-billion-dollar antibiotic drug, Zithromax. Dr. Hamsher spent his early career in Pfizer Central Research as a Scientist, Research Manager, and Assistant Director in pharmaceutical chemical research. Dr. Hamsher received a BA from Wabash College, a MS in organic chemistry from Southern Illinois University, and a PhD in organic chemistry from Purdue University.
Dr. Hamsher is responsible for Licensing and Business Development activities at Cytogel and has extensive experience in the pharmaceutical industry in licensing as well as research and development. Responsibilities at Cytogel have included initiating and maintaining relationships with industry experts and pharmaceutical companies around the world, which includes dissemination of key information, making presentations and involvement in business decisions relating to licensing activities. In addition to Business Development, Dr. Hamsher is involved in the research, development, and planning of Cytogel’s new drug candidate, CYT-1010.
Prior to joining Cytogel in 2008, Dr. Hamsher was President of Hamsher Associates International, a private Healthcare consulting company. Much of his professional career was with Pfizer, Inc., most recently as Senior Director of Licensing and Business Development for worldwide pharmaceuticals. Responsibilities included new drug discovery, evaluation, deal structure and negotiation, and presentation of overall projects to Senior Management for approval. Most notable during this tenure was responsibility for the early stage licensing and deal structure/negotiation for the multi-billion-dollar antibiotic drug, Zithromax. Dr. Hamsher spent his early career in Pfizer Central Research as a Scientist, Research Manager, and Assistant Director in pharmaceutical chemical research. Dr. Hamsher received a BA from Wabash College, a MS in organic chemistry from Southern Illinois University, and a PhD in organic chemistry from Purdue University.
Ms. Driver is a seasoned leader with more than 25 years in the pharmaceutical industry, joining Cytogel as a consultant in 2015. She has supported the company with program and project management, including outsourcing preclinical studies, compound development, manufacturing, regulatory services and planning for the firm’s upcoming Phase 2 clinical conduct.
As an accomplished pharmaceutical global supply chain and operations executive with extensive experience in cGMP, cGCP, quality management and program management, Ms. Driver has held leadership positions at Pfizer in Global Clinical Supply Chain and Development Operations. As an independent consultant, she has provided program management and operations support, including contacts with vendors and independent consultants to provide services for preclinical and clinical trial services.
Ms. Driver holds a BA degree from Southern Methodist University.
Ms. Driver is a seasoned leader with more than 25 years in the pharmaceutical industry, joining Cytogel as a consultant in 2015. She has supported the company with program and project management, including outsourcing preclinical studies, compound development, manufacturing, regulatory services and planning for the firm’s upcoming Phase 2 clinical conduct.
As an accomplished pharmaceutical global supply chain and operations executive with extensive experience in cGMP, cGCP, quality management and program management, Ms. Driver has held leadership positions at Pfizer in Global Clinical Supply Chain and Development Operations. As an independent consultant, she has provided program management and operations support, including contacts with vendors and independent consultants to provide services for preclinical and clinical trial services.
Ms. Driver holds a BA degree from Southern Methodist University.